Chris Jackson

Chris Jackson has been in diagnostic lab testing for over 30 years focusing on health care sales and marketing. Mr. Jackson has launched over 35 products during his career, with the majority in the field of women’s health & reproductive medicine.

From 1998-2006, Chris was National Sales Director of U.S. sales for Adeza biomedical. Adeza’s key product was an assay known as Fetal Fibronectin, used by OBGYN’s to identify women at risk of preterm birth. He took the company from $2M in sales in 1998 to $45M in 2006. In 2004, the company had a successful IPO and was eventually purchased but Cytech (now Hologic) in 2007. From his experience at Adeza and his deep understanding of Women’s Health, Chris started Cicero Diagnostics after negotiating exclusive rights to a unique biomarker highly associated with endometriosis and infertility held by the University of North Carolina. Since Cicero Diagnostics launch in 2017, the company has seen explosive growth in test use, research publications and a million dollar NIH small business (SBIR) grant. In addition, ReceptivaDx’s growing social media presence has provided access to educational information on the value of the test across multiple channels worldwide.